What is William Blair’s Forecast for AVIR Q1 Earnings?

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) – Analysts at William Blair issued their Q1 2026 earnings estimates for shares of Atea Pharmaceuticals in a report issued on Friday, March 7th. William Blair analyst A. Hsieh expects that the company will post earnings per share of ($0.40) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Atea Pharmaceuticals’ current full-year earnings is ($2.01) per share. William Blair also issued estimates for Atea Pharmaceuticals’ Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.59) EPS and FY2027 earnings at ($1.60) EPS.

Atea Pharmaceuticals (NASDAQ:AVIR) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05).

Atea Pharmaceuticals Trading Down 0.3 %

AVIR stock opened at $2.99 on Monday. Atea Pharmaceuticals has a one year low of $2.75 and a one year high of $4.18. The firm has a market capitalization of $252.54 million, a PE ratio of -1.44 and a beta of 0.18. The firm has a 50-day moving average of $3.15 and a two-hundred day moving average of $3.34.

Institutional Trading of Atea Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC lifted its position in shares of Atea Pharmaceuticals by 223.3% in the fourth quarter. Squarepoint Ops LLC now owns 50,750 shares of the company’s stock worth $170,000 after purchasing an additional 35,053 shares in the last quarter. Tang Capital Management LLC lifted its position in shares of Atea Pharmaceuticals by 3.9% in the fourth quarter. Tang Capital Management LLC now owns 4,788,912 shares of the company’s stock worth $16,043,000 after purchasing an additional 181,852 shares in the last quarter. Shay Capital LLC lifted its position in shares of Atea Pharmaceuticals by 72.5% in the fourth quarter. Shay Capital LLC now owns 30,633 shares of the company’s stock worth $103,000 after purchasing an additional 12,871 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of Atea Pharmaceuticals by 31.5% in the fourth quarter. ProShare Advisors LLC now owns 25,733 shares of the company’s stock worth $86,000 after purchasing an additional 6,163 shares in the last quarter. Finally, Newtyn Management LLC lifted its position in shares of Atea Pharmaceuticals by 52.6% in the fourth quarter. Newtyn Management LLC now owns 580,000 shares of the company’s stock worth $1,943,000 after purchasing an additional 200,000 shares in the last quarter. 86.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Atea Pharmaceuticals

In other Atea Pharmaceuticals news, Director Franklin M. Berger sold 359,606 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the sale, the director now directly owns 451,897 shares of the company’s stock, valued at approximately $1,287,906.45. This represents a 44.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 17.80% of the company’s stock.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.